These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

89 related items for PubMed ID: 12774029

  • 1. Renal sodium retention in portal hypertension and hepatorenal reflex: from practice to science.
    Jiménez-Sáenz M, Soria IC, Bernardez JR, Gutierrez JM.
    Hepatology; 2003 Jun; 37(6):1494; author reply 1494-5. PubMed ID: 12774029
    [No Abstract] [Full Text] [Related]

  • 2. Hepatorenal syndrome.
    Gattoni A, Marotta F, Vangieri B, Pisani G, Cristiano F.
    Clin Ter; 2004 Sep; 155(9):375-89. PubMed ID: 15700631
    [Abstract] [Full Text] [Related]

  • 3. [Study on the expressions and roles of renal heat shock protein 72 and Toll-like receptor 4 in hepatorenal syndrome in rat].
    Yan CG, Zhu DF, Wang F.
    Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2007 Dec; 19(12):731-4. PubMed ID: 18093430
    [Abstract] [Full Text] [Related]

  • 4. Pathophysiological basis of pharmacotherapy in the hepatorenal syndrome.
    Møller S, Bendtsen F, Henriksen JH.
    Scand J Gastroenterol; 2005 May; 40(5):491-500. PubMed ID: 16036500
    [Abstract] [Full Text] [Related]

  • 5. Type-2 hepatorenal syndrome and refractory ascites: role of transjugular intrahepatic portosystemic stent-shunt in eighteen patients with advanced cirrhosis awaiting orthotopic liver transplantation.
    Testino G, Ferro C, Sumberaz A, Messa P, Morelli N, Guadagni B, Ardizzone G, Valente U.
    Hepatogastroenterology; 2003 May; 50(54):1753-5. PubMed ID: 14696397
    [Abstract] [Full Text] [Related]

  • 6. Review article: pathogenesis and pathophysiology of hepatorenal syndrome--is there scope for prevention?
    Møller S, Henriksen JH.
    Aliment Pharmacol Ther; 2004 Sep; 20 Suppl 3():31-41; discussion 42-3. PubMed ID: 15335398
    [Abstract] [Full Text] [Related]

  • 7. [Hepatorenal syndrome].
    Jarcuska P, Fraenkel E, Fehér J.
    Orv Hetil; 2005 Oct 02; 146(40):2073-81. PubMed ID: 16259336
    [Abstract] [Full Text] [Related]

  • 8. Splanchnic and systemic vasodilatation: the patient.
    Tsai MH.
    J Clin Gastroenterol; 2007 Oct 02; 41 Suppl 3():S266-71. PubMed ID: 17975476
    [Abstract] [Full Text] [Related]

  • 9. [Diagnostics and therapy of hepatorenal syndrome. Recommendations of of the working group on portal hypertension of the Czech Hepatology Society and the J. E. Purkinje Czech Medical Society].
    Brůha R, Skupiny C, Balihar K, Drastich P, Hůlek P, Lata J, Petrtýl J, Procházka V, Spicák J, Vanásek T, Volfová M, Zdenek P, Czech Hepatology Society, J E Purkinje Czech Medical Society.
    Vnitr Lek; 2006 Jun 02; 52(6):649-50. PubMed ID: 16871772
    [Abstract] [Full Text] [Related]

  • 10. Portal hypertension.
    Garcia-Tsao G.
    Curr Opin Gastroenterol; 2006 May 02; 22(3):254-62. PubMed ID: 16550040
    [Abstract] [Full Text] [Related]

  • 11. Transjugular intrahepatic portosystemic shunt in the management of ascites and hepatorenal syndrome.
    Senzolo M, Cholongitas E, Tibballs J, Burroughs A, Patch D.
    Eur J Gastroenterol Hepatol; 2006 Nov 02; 18(11):1143-50. PubMed ID: 17033432
    [Abstract] [Full Text] [Related]

  • 12. [Hepatorenal syndrome in patients with liver cirrhosis].
    Zaza S, Bonny O, Liaudet L.
    Nephrol Ther; 2005 Jul 02; 1(3):174-82. PubMed ID: 16895684
    [Abstract] [Full Text] [Related]

  • 13. Liver-kidney pathophysiological interrelationships in liver diseases.
    Gentilini P, La Villa G.
    Dig Liver Dis; 2008 Dec 02; 40(12):909-19. PubMed ID: 18621592
    [Abstract] [Full Text] [Related]

  • 14. [Managing the complications of cirrhosis].
    Deltenre P, Mathurin P, Barraud H, Bronowicki JP, Jacquet E, Puche P, Jaber S, Navarro F, Pageaux GP.
    Rev Prat; 2005 Sep 30; 55(14):1555-63. PubMed ID: 16255297
    [Abstract] [Full Text] [Related]

  • 15. [Role of platelet activating factor in hepatorenal syndrome].
    Xie DS, Xie YT.
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2005 Jun 30; 30(3):349-51. PubMed ID: 16045031
    [Abstract] [Full Text] [Related]

  • 16. Oxidative stress, nitric oxide production, and renal sodium handling in leptin-induced hypertension.
    Beltowski J, Wójcicka G, Marciniak A, Jamroz A.
    Life Sci; 2004 Apr 30; 74(24):2987-3000. PubMed ID: 15051422
    [Abstract] [Full Text] [Related]

  • 17. [Hepatorenal syndrome].
    Radziszewski A, Sułowicz W.
    Przegl Lek; 2006 Apr 30; 63(7):573-8. PubMed ID: 17203812
    [Abstract] [Full Text] [Related]

  • 18. Defective renal dopamine D1 receptor function contributes to hyperinsulinemia-mediated hypertension.
    Ahmad Banday A, Lokhandwala MF.
    Clin Exp Hypertens; 2006 Nov 30; 28(8):695-705. PubMed ID: 17132536
    [Abstract] [Full Text] [Related]

  • 19. Aquaporin-1 and aquaporin-2 urinary excretion in cirrhosis: Relationship with ascites and hepatorenal syndrome.
    Esteva-Font C, Baccaro ME, Fernández-Llama P, Sans L, Guevara M, Ars E, Jiménez W, Arroyo V, Ballarín JA, Ginès P.
    Hepatology; 2006 Dec 30; 44(6):1555-63. PubMed ID: 17133493
    [Abstract] [Full Text] [Related]

  • 20. Hepatorenal syndrome: pathogenesis and novel pharmacological targets.
    Barada K.
    Curr Opin Pharmacol; 2004 Apr 30; 4(2):189-97. PubMed ID: 15063365
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.